TARSUS PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
TARSUS PHARMACEUTICALS, INC. (TARS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$64.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-23
- TARSUS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$64.36M.
- TARSUS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$115.55M.
- TARSUS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$135.89M.
- TARSUS PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$62.09M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$64.36M 10-K · filed 2026-02-23 |
| 2024-12-31 | -$115.55M 10-K · filed 2026-02-23 |
| 2023-12-31 | -$135.89M 10-K · filed 2026-02-23 |
| 2022-12-31 | -$62.09M 10-K · filed 2025-02-25 |
| 2021-12-31 | -$13.77M 10-K · filed 2023-03-17 |
| 2020-12-31 | -$26.81M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |